Real world evidence (RWE) refers to data collected outside the context of traditional clinical trials, such as observational studies, registries, and electronic health records. RWE can provide valuable insights into the safety, effectiveness, and real-world use of drugs, and has the potential to transform drug development.
Some of the opportunities of real world evidence in drug development include:
1. Improved patient recruitment: RWE can help identify patient populations that are typically underrepresented in clinical trials, such as elderly patients, patients with multiple comorbidities, and those with rare diseases. This can help improve patient recruitment and enable more representative clinical trials.
2. Enhance clinical trial design: RWE can help inform the design of clinical trials, for example, by identifying appropriate endpoints, understanding patient demographics, and identifying potential confounding factors that need to be accounted for.
Identify safety concerns: RWE can help identify safety concerns that may not have been detected in clinical trials, especially those related to long-term use or rare adverse events. This can help improve post-marketing surveillance and ensure that drugs are used safely in the real world.
3. Better understanding of effectiveness: RWE can provide insights into the effectiveness of drugs in the real world, including how drugs are used in combination with other treatments, and how patient outcomes vary across different subpopulations.
4. Accelerate drug development: By leveraging RWE, drug development timelines can be accelerated as fewer resources are required for clinical trials, making it easier to conduct larger and more complex studies. Additionally, RWE can help optimize the design of clinical trials, reducing the likelihood of failed trials and resulting in faster regulatory approvals.
In summary, real world evidence has the potential to improve drug development in a number of ways, including patient recruitment, clinical trial design, safety monitoring, and accelerating drug development timelines. By leveraging RWE, drug developers can gain a better understanding of how drugs work in the real world, which can ultimately improve patient outcomes.
Share this story...
Real World Evidence (RWE) 101 – ‘Interventional’ Clinical Trial vs Non-Interventional Study
RWE 101 - 'Interventional' Clinical Trial vs Non-Interventional Study Interventional Clinical Trial: In this type of study, researchers actively intervene by assigning participants to different groups, administering specific treatments, [...]
Real World Evidence (RWE) 101 – Are the terms ‘clinical study’ and ‘clinical trial’ synonymous in the context of non-interventional studies?
RWE 101 - Are the terms 'clinical study' and 'clinical trial' synonymous in the context of non-interventional studies? No, "clinical study" and "clinical trial" are not necessarily synonymous in [...]
Real World Evidence (RWE) 101 – The Importance of Regulatory Definitions
RWE 101 - The Importance of Regulatory Definitions "Words are powerful"Regulatory definitions are important in the context of real-world evidence (RWE) studies and real-world research for several reasons:[1] Consistency: [...]
Real World Evidence (RWE) 101 – Regulatory Compliance
RWE 101 - Regulatory Compliance Regulatory compliance in the context of real-world evidence (RWE) refers to ensuring that the generation and use of RWE for regulatory purposes [...]
Real World Evidence (RWE) 101 – Regulatory Intelligence
RWE 101 - Regulatory Intelligence In the context of real-world evidence (RWE) and real-world research (RWR), regulatory intelligence refers to the process of gathering, analyzing, and interpreting regulatory information [...]
Real World Evidence (RWE) 101 – Regulatory Science
RWE 101 - Regulatory Science Regulatory science is a field of study that involves the application of scientific methods, principles, and data to the development and evaluation of regulatory [...]







